📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Ernexa

1.1 - Company Overview

Ernexa Logo

Ernexa

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of clinical-stage biopharmaceutical research and development of cytokine-based therapies, using mRNA to express reprogramming proteins for allogeneic pluripotent stem cell-derived CAR-T and CAR-NK therapies and to express gene-editing proteins, including UltraSlice, to deactivate, repair, insert, replace, or delete specific DNA sequences, and employing LNP technology, such as ToRNAdo, for efficient and safe delivery of mRNA cargo into human cells.

Products and services

  • Cell Reprogramming: mRNA-based system that expresses reprogramming proteins to architect allogeneic pluripotent stem cell-derived CAR-T and CAR-NK therapies
  • Gene Delivery: LNP-based product, ToRNAdo™, delivers mRNA cargo efficiently and safely into human cells using lipid nanoparticle (LNP) technology
  • Gene Editing: mRNA-expressed gene-editing proteins, including UltraSlice™, deactivate, repair, insert, replace, or delete specific DNA sequences to engineer targeted genomic changes

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Ernexa

Nativis Logo

Nativis

HQ: United States Website
  • Description: Provider of therapeutic modalities in development for the treatment of serious disease.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Nativis company profile →
Ratio Therapeutics Logo

Ratio Therapeutics

HQ: United States Website
  • Description: Provider of clinical-phase radiopharmaceuticals for solid tumors, with the Trillium platform for pharmacokinetic modulation to improve tumor-targeted delivery, the Macropa chelator for actinium-225 conjugation, FAP-targeted therapies including a PET diagnostic, and a Granzyme B PET imaging agent to monitor immune response in cancer and inflammatory diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Ratio Therapeutics company profile →
HistoSonics Logo

HistoSonics

HQ: United States Website
  • Description: Provider of non-invasive medical devices and technologies for interventional radiology and surgical robotics.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full HistoSonics company profile →
Pheon Therapeutics Logo

Pheon Therapeutics

HQ: United Kingdom Website
  • Description: Provider of antibody-drug conjugate (ADC) programs for difficult-to-treat cancers. Offerings include PHN-010, an ADC targeting a transmembrane protein over-expressed in multiple solid tumors with low expression in healthy tissues; development of first-in-class solid tumor programs with in vivo proof of concept; and proprietary payloads to overcome resistance, featuring novel modes of action and tunable potency.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Pheon Therapeutics company profile →
Xoft Logo

Xoft

HQ: United States Website
  • Description: Provider of electronic brachytherapy (eBx) systems for radiation oncology, including the Elekta Xoft Axxent system with miniaturized X-ray source, Axxent Controller, SPX Controller for surface treatments, Axxent X-ray Source, balloon and extended balloon applicators for intracavitary and intraoperative therapy, and Radion Hub Peer Review cloud software for network-wide peer review to improve patient safety and quality care.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Xoft company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Ernexa

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Ernexa

2.2 - Growth funds investing in similar companies to Ernexa

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Ernexa

4.2 - Public trading comparable groups for Ernexa

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Ernexa

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Ernexa

What does Ernexa do?

Ernexa is a provider of clinical-stage biopharmaceutical research and development of cytokine-based therapies, using mRNA to express reprogramming proteins for allogeneic pluripotent stem cell-derived CAR-T and CAR-NK therapies and to express gene-editing proteins, including UltraSlice, to deactivate, repair, insert, replace, or delete specific DNA sequences, and employing LNP technology, such as ToRNAdo, for efficient and safe delivery of mRNA cargo into human cells.

Who are Ernexa's competitors?

Ernexa's competitors and similar companies include Nativis, Ratio Therapeutics, HistoSonics, Pheon Therapeutics, and Xoft.

Where is Ernexa headquartered?

Ernexa is headquartered in United States.

How many employees does Ernexa have?

Ernexa has 1,000 employees 🔒.

When was Ernexa founded?

Ernexa was founded in 2010 🔒.

What sector and industry vertical is Ernexa in?

Ernexa is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Ernexa

Who are the top strategic acquirers in Ernexa's sector and industry

Top strategic M&A buyers and acquirers in Ernexa's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Ernexa?

Top strategic M&A buyers groups and sectors for Ernexa include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Ernexa's sector and industry vertical

Which are the top PE firms investing in Ernexa's sector and industry vertical?

Top PE firms investing in Ernexa's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Ernexa's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Ernexa's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Ernexa's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Ernexa include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Ernexa's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Ernexa?

The key public trading comparables and valuation benchmarks for Ernexa include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Ernexa for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Ernexa with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Ernexa's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Ernexa with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Ernexa's' sector and industry vertical?

Access recent funding rounds and capital raises in Ernexa's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Ernexa